Abstract 2129: Predictive response biomarkers from Phase I clinical trial of a SIRPalpha inhibitor BI765063, stand-alone and in combination with ezabenlimab, a PD1 inhibitor, in patients with advanced solid tumors

Autor: Stéphane Champiat, Philippe A. Cassier, Nuria Kotecki, Carlos Gomez-Roca, Iphigenie Korakis, Ouali Kaissa, Antoine Italiano, Mabrouk M. Elgadi, Thomas Vandewalle, Isabelle Girault, Nina Salabert-Le Guen, Donogh O’Brien, Nicolas Poirier, Bérangère Vasseur, Dominique Costantini, Claudia Fromond, Françoise Bono, Jean-Pierre Delord

Publikováno v: Cancer Research. 83:2129-2129

Background: Signal Regulatory Protein α [SIRPα] is an inhibitory membrane receptor expressed by myeloid cells (macrophages and myeloid-derived suppressor cells, MDSCs) and specifically binds to CD47. BI765063 is a selective anti-SIRPα monoclonal a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::929ce79085421e3bd7b5f2755e2fd14f
https://doi.org/10.1158/1538-7445.am2023-2129

Picornavirus internal ribosome entry site elements target RNA cleavage events induced by the herpes simplex virus virion host shutoff protein

Autor: Mabrouk M. Elgadi, James R. Smiley

Publikováno v: Journal of virology. 73(11)

Many viruses selectively inhibit host cell protein synthesis as a key element of their strategy of reprogramming the cellular biosynthetic machinery to support efficient virus replication. In the best-understood cases, picornaviruses employ multiple

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1f5ad9f208bf34e348e7929693053ae
https://pubmed.ncbi.nlm.nih.gov/10516030

654. Targeting Adenoviral Vectors for Use in Breast Cancer Gene Therapy

Autor: Mabrouk M. Elgadi, Leonard I. Wiebe, Mary M. Hitt, Chang-Xin Shi, Alan D. DeSilva, Gianluca Bossi

Publikováno v: Molecular Therapy. 13:S252

The results of many cancer gene therapy clinical trials to date suggest that improvements must be made to increase gene delivery, expression levels, and/or potency of the genes in order to induce tumour regression. However, increasing any of these pa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bab2e6792e9a8fa5bc81369662b76784
https://doi.org/10.1016/j.ymthe.2006.08.730

⁸⁹ Zr-immuno-PET using the anti-LAG-3 tracer [ ⁸⁹ Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC.

Autor: Miedema IHC; Department of Medical Oncology, Amsterdam UMC location Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, the Netherlands.; Imaging and Biomarkers, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, the Netherlands., Huisman MC; Imaging and Biomarkers, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, the Netherlands.; Department of Radiology and Nuclear Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, the Netherlands., Zwezerijnen GJC; Imaging and Biomarkers, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, the Netherlands.; Department of Radiology and Nuclear Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, the Netherlands., Grempler R; Department of Translational Medicine & Clinical Pharmacology, Boehringer Ingelheim Pharmaceuticals, 900 Ridgebury Road, Ridgefield, CT, 06877, USA., Pitarch AP; Department of Translational Medicine & Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Strasse 65, 88400, Biberach and der Riss, Germany., Thiele A; Department of Translational Medicine & Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Strasse 65, 88400, Biberach and der Riss, Germany., Hesse R; Department of Translational Medicine & Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Strasse 65, 88400, Biberach and der Riss, Germany., Elgadi M; Department of Translational Medicine & Clinical Pharmacology, Boehringer Ingelheim Pharmaceuticals, 900 Ridgebury Road, Ridgefield, CT, 06877, USA., Peltzer A; Department of Translational Medicine & Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Strasse 65, 88400, Biberach and der Riss, Germany., Vugts DJ; Imaging and Biomarkers, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, the Netherlands.; Department of Radiology and Nuclear Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, the Netherlands., van Dongen GAMS; Imaging and Biomarkers, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, the Netherlands.; Department of Radiology and Nuclear Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, the Netherlands., de Gruijl TD; Department of Medical Oncology, Amsterdam UMC location Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, the Netherlands.; Cancer Biology and Immunology, Cancer Center Amsterdam, De Boelelaan 1117, 1018 HV, Amsterdam, the Netherlands., Menke-van der Houven van Oordt CW; Department of Medical Oncology, Amsterdam UMC location Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, the Netherlands. c.menke@amsterdamumc.nl.; Imaging and Biomarkers, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, the Netherlands. c.menke@amsterdamumc.nl., Bahce I; Imaging and Biomarkers, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, the Netherlands.; Department of Pulmonary Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, the Netherlands.

Publikováno v: European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2023 Jun; Vol. 50 (7), pp. 2068-2080. Date of Electronic Publication: 2023 Mar 02.

Investigation of the effect of food and omeprazole on the relative bioavailability of a single oral dose of 240 mg faldaprevir, a selective inhibitor of HCV NS3/4 protease, in an open-label, randomized, three-way cross-over trial in healthy participants.

Autor: Wu J; Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA., Gießmann T; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany., Lang B; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany., Elgadi M; Boehringer Ingelheim Canada Ltd/Ltee, Burlington, ON, Canada., Huang F; Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA.

Publikováno v: The Journal of pharmacy and pharmacology [J Pharm Pharmacol] 2016 Apr; Vol. 68 (4), pp. 459-66. Date of Electronic Publication: 2016 Mar 28.